Literature DB >> 28030378

Does lifestyle contribute to disease severity in patients with inherited lipid disorders?

Benoit J Arsenault1, Nicolas Perrot, Patrick Couture.   

Abstract

PURPOSE OF REVIEW: Patients with familial hypercholesterolemia, familial combined hyperlipidemia and hyperlipoprotein(a) are at high cardiovascular risk. Increasing evidence suggest that lifestyle-related risk factors such as physical inactivity, and poor diet quality could influence cardiovascular risk in these patients. Our objective is to review the evidence that supports the role of lifestyle-related factors in the prediction of cardiovascular risk in patients with inherited lipid disorders. RECENT
FINDINGS: Recent studies have shown that smoking, a poor diet quality, physical inactivity, fitness levels, abdominal obesity, insulin resistance, and type 2 diabetes were associated with the presence of atherosclerosis and long-term cardiovascular outcomes in patients with familial hypercholesterolemia. Recent evidence also suggest that managing other cardiovascular risk factors such as cholesterol levels, obesity, glycemic control, blood pressure, smoking, physical inactivity, and diet quality could reduce long-term cardiovascular risk associated with hyperlipoprotein(a). Whether targeting these risk factors could ultimately decrease cardiovascular risk in these patients remains unknown.
SUMMARY: Although reducing the number of atherogenic apolipoprotein-B containing particle with lipid-lowering therapy represents the cornerstone of treatment of patients with inherited lipid disorders, lifestyle-related risk factors such as physical inactivity and poor diet quality need to be targeted for the optimal management of these high-risk patients.

Entities:  

Mesh:

Year:  2017        PMID: 28030378     DOI: 10.1097/MOL.0000000000000387

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  6 in total

Review 1.  Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.

Authors:  Ivan Pećin; Merel L Hartgers; G Kees Hovingh; Ricardo Dent; Željko Reiner
Journal:  Eur J Prev Cardiol       Date:  2017-06-23       Impact factor: 7.804

2.  Supplements of an aqueous combination of Justicia adhatoda and Ocimum tenuiflorum boost antioxidative effects and impede hyperlipidemia.

Authors:  Ifrahim Iqbal Chowdhury; Md Atiar Rahman; Mohammad A Hashem; M Mosharef Hossain Bhuiyan; Dina Hajjar; Walla Alelwani; Arwa A Makki; Md Areeful Haque; Jitbanjong Tangpong; M Taher Bin Bakhtiar
Journal:  Animal Model Exp Med       Date:  2020-04-29

Review 3.  Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management.

Authors:  Maria Mytilinaiou; Ioannis Kyrou; Mike Khan; Dimitris K Grammatopoulos; Harpal S Randeva
Journal:  Front Pharmacol       Date:  2018-07-12       Impact factor: 5.810

4.  A Comorbidity Model of Myocardial Ischemia/Reperfusion Injury and Hypercholesterolemia in Rat Cardiac Myocyte Cultures.

Authors:  András Makkos; Ágnes Szántai; János Pálóczi; Judit Pipis; Bernadett Kiss; Paola Poggi; Péter Ferdinandy; Alexandros Chatgilialoglu; Anikó Görbe
Journal:  Front Physiol       Date:  2020-01-09       Impact factor: 4.566

5.  Reducing cardiovascular disease risk among families with familial hypercholesterolaemia by improving diet and physical activity: a randomised controlled feasibility trial.

Authors:  Fiona Jane Kinnear; Fiona E Lithander; Aidan Searle; Graham Bayly; Christina Wei; David J Stensel; Alice E Thackray; Linda Hunt; Julian P H Shield
Journal:  BMJ Open       Date:  2020-12-28       Impact factor: 2.692

6.  The Ameliorative Effect of COST on Diet-Induced Lipid Metabolism Disorders by Regulating Intestinal Microbiota.

Authors:  Huimin You; Xiaoyi Deng; Yan Bai; Jincan He; Hua Cao; Qishi Che; Jiao Guo; Zhengquan Su
Journal:  Mar Drugs       Date:  2022-07-07       Impact factor: 6.085

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.